Lupin Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) to market the generic version of the anti-epileptic drug Keppra. The total sales of this drug in the US market is estimated to be $13 billion. Keppra was the patented drug of European drug maker UCB pharma. It lost the patent for this drug in 2008. The drug has been growing at 23% every year with a total sales of $1.74 billion
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1874.00 |
| Dr. Reddys Lab | 1295.00 |
| Cipla | 1321.95 |
| Zydus Lifesciences | 946.80 |
| Lupin | 2271.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: